Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report

Osamu Honjo,Terufumi Kubo,Fumiko Sugaya,Takahiro Nishizaka,Koji Kato,Yoshihiko Hirohashi,Hiroki Takahashi,Toshihiko Torigoe

Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report

2019

Osamu Honjo
Terufumi Kubo
Fumiko Sugaya
Takahiro Nishizaka
Koji Kato
Yoshihiko Hirohashi
Hiroki Takahashi
Toshihiko Torigoe

Background Immune checkpoint inhibitors (ICIs) have provided more options in the treatment of lung cancer. However, ICIs can cause several unfavorable reactions generally referred to as immune-related adverse effects.

Keywords:

Pleomorphic carcinoma
Cytokine release syndrome
Nivolumab
Oncology
Treatment of lung cancer
Purpura fulminans
Lung
Immune checkpoint
Internal medicine
Medicine
Adverse effect
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations